scholarly journals Safety and pharmacokinetics of olokizumab, an anti‐IL‐6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study

2014 ◽  
Vol 3 (5) ◽  
pp. 388-395 ◽  
Author(s):  
Kosmas Kretsos ◽  
Georg Golor ◽  
Astrid Jullion ◽  
Matthew Hickling ◽  
Suzanne McCabe ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Phase I ◽  
Phase I Study ◽  
Healthy Male ◽  
Healthy Male Volunteers ◽  
Male Volunteers

Multiple Rising Doses of Oral BI 1358894 in Healthy Male Volunteers: A Phase I Study to Investigate Safety and Tolerability

2020 ◽  
Vol 87 (9) ◽  
pp. S417-S418
Author(s):  
Markus Goettel ◽  
Lena Herich ◽  
Sabrina Wiebe ◽  
Rene Fuertig ◽  
Vikas Sharma ◽  
...  
Keyword(s):  
Phase I ◽  
Phase I Study ◽  
Healthy Male ◽  
Healthy Male Volunteers ◽  
Male Volunteers

A phase I study to determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib (IRESSA) in healthy male volunteers

2005 ◽  
Vol 56 (6) ◽  
pp. 557-562 ◽  
Author(s):  
Mireille V. Cantarini ◽  
Merran P. Macpherson ◽  
Anna L. Marshall ◽  
Anna V. Robinson ◽  
Christopher J. Bailey
Keyword(s):  
Oral Dose ◽  
Phase I ◽  
Phase I Study ◽  
Healthy Male ◽  
Healthy Male Volunteers ◽  
Male Volunteers

Hormonal effects of MPV-2213ad, a novel, competitive aromatase inhibitor in healthy male volunteers. A phase I study

1997 ◽  
Vol 33 ◽  
pp. S250
Author(s):  
O. Ahokoski ◽  
K. Irjaia ◽  
R. Huupponen ◽  
K. Halonen ◽  
E. Salminen ◽  
...  
Keyword(s):  
Phase I ◽  
Aromatase Inhibitor ◽  
Phase I Study ◽  
Healthy Male ◽  
Hormonal Effects ◽  
Healthy Male Volunteers ◽  
Male Volunteers

Phase I study in healthy male volunteers with the non-steroidal aromatase inhibitor CGS 20267

1990 ◽  
Vol 26 (2) ◽  
pp. 173 ◽  
Author(s):  
P. Trunet ◽  
Ph. Müller ◽  
A. Bhatnagar ◽  
H. Chaudri ◽  
I. Beh ◽  
...  
Keyword(s):  
Phase I ◽  
Aromatase Inhibitor ◽  
Phase I Study ◽  
Healthy Male ◽  
Healthy Male Volunteers ◽  
Male Volunteers ◽  
Cgs 20267

Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study

Endocrine ◽  
2012 ◽  
Vol 42 (2) ◽  
pp. 366-374 ◽  
Author(s):  
Christoph Beglinger ◽  
Ke Hu ◽  
Ying Wang ◽  
Emmanuel Bouillaud ◽  
Christelle Darstein ◽  
...  
Keyword(s):  
Phase I ◽  
Phase I Study ◽  
Healthy Male ◽  
Double Blind ◽  
Once Daily ◽  
Double Blind Placebo ◽  
Healthy Male Volunteers ◽  
Male Volunteers

First-In-Human Study of Oral BI 1358894 in Healthy Male Volunteers: A Phase I Study to Investigate Safety and Tolerability

2020 ◽  
Vol 87 (9) ◽  
pp. S289-S290
Author(s):  
Markus Goettel ◽  
Josef Höfler ◽  
Rene Fuertig ◽  
Vikas Sharma ◽  
Markus Göttel
Keyword(s):  
Phase I ◽  
Phase I Study ◽  
Human Study ◽  
Healthy Male ◽  
Healthy Male Volunteers ◽  
Male Volunteers
Sign in / Sign up

Export Citation Format

Share Document